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Abstract
Objectives: We investigated whether changes in mammographic technique and screening policy have improved mammographic sensitivity and elongated the mean sojourn time since the introduction of biennial breast cancer screening in Nijmegen, the Netherlands, in 1975. 
Methods: Maximum Likelihood Estimation (MLE), Non-Linear Regression (NLR) and Markov Chain Monte Carlo simulation (MCMC) were used to estimate test sensitivity, mean sojourn time and underlying breast cancer incidence in four time periods covering forty years of breast cancer screening in Nijmegen (1975-2012). 
Results: MLE estimated a test sensitivity of approximately 90% and a mean sojourn time around 3 years, while the estimates based on NLR and MCMC were 80% and 4 years, respectively. All three methods estimated a rise in the underlying breast cancer incidence over time, with approximately one case more per 1,000 women per year in the final period compared with the first period. 
Conclusions: The three methods showed a slightly higher mammographic sensitivity and a longer mean sojourn time in the last period, after the introduction of digital mammography. Estimates were more realistic for the more sophisticated methods, NLR and MCMC, while the simple closed form approximation of MLE led to rather high estimates for sensitivity in the early periods.
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Introduction
Analyses of the national breast cancer screening program in the Netherlands have shown that breast cancer can be detected early and that breast cancer mortality has decreased since the introduction of screening, whereas estimates of overdiagnosis are considered acceptable (1). The start of the Dutch breast cancer screening program in 1989 was preceded by  pilot studies in Utrecht and Nijmegen  ADDIN EN.CITE (2, 3). Since the introduction of  biennial breast cancer screening in Nijmegen in 1975, the technique of mammography has improved and has recently changed from analogue to digital. The hypothesis is that these technological advancements as well as other changes within the program, e.g. to increase the referral rate, led to an improved test sensitivity of mammography and an elongation of the mean sojourn time. Sojourn time can be defined as the duration of the preclinical screen-detectable phase, i.e. the period during which a woman is asymptomatic but the breast cancer is detectable by mammography (4). Test sensitivity is the probability that a woman with asymptomatic breast cancer undergoing mammographic screening during the preclinical detectable phase will have her breast cancer detected by the test (4). Since the effectiveness of breast cancer screening crucially depends on test sensitivity and mean sojourn time, these measures of interest were estimated when the breast cancer screening program was introduced. However, these estimates have not been updated after the  technological advancements in mammography and policy changes in the program while there known suitable measures of the screening effect  ADDIN EN.CITE (5).
The challenge of quantifying mean sojourn time is that it is not directly observable. However, it can be estimated. The easiest method to estimate mean sojourn time is to use tumor volume doubling times as a proxy, since mean sojourn time can be seen as a measure of tumor growth  ADDIN EN.CITE (6, 7). Therefore, several methods, varying from simple to complex, for the estimation of mean sojourn time have been developed based on screening frequency data and breast cancer prevalence and incidence data which are easily obtainable. Methods that are described in the current body of literature include simple methods based on the ratio of prevalence of the disease at first screening examination related to the expected annual incidence rate (8), parametric models assuming a specific distribution for sojourn time  ADDIN EN.CITE (9, 10), nonparametric methods with time split into discrete intervals (11), simulation models with patient-level data  ADDIN EN.CITE (12), and Markov models simulating the natural history of chronic diseases (13). As there is no gold standard to estimate mean sojourn time, the reliability of all these estimation methods remains unclear. Therefore we applied three different estimation methods in order to investigate whether they gave similar results which can still be incorrect. Since our interest is in measuring the effect of technological advancements in mammography and changes in policy over several decades, we want to obtain multiple estimates for test sensitivity and mean sojourn time. The most relevant change is the shift from analogue to digital mammography in 2007 and its accompanying higher breast cancer detection rate  ADDIN EN.CITE (14).
In this paper, we investigate whether technological advancements of mammography and changes in screening policy have improved the test sensitivity of mammography  and have elongated the correlated mean sojourn time. We illustrate this by applying three different estimation methods using almost forty years of data from the Nijmegen breast cancer screening program.


Methods
Nijmegen breast cancer screening, 1975-2012
A pilot study on biennial breast cancer screening with analogue mammography started in 1975 in the city of Nijmegen, the Netherlands. Further details on the pilot study can be found in the paper by Otten et al.  ADDIN EN.CITE (15). After promising results from the breast cancer screening pilot studies in Nijmegen and Utrecht, the Dutch government decided to implement a nationwide biennial breast cancer screening program  ADDIN EN.CITE (2, 3, 16). Thus from 1989 onwards, the Nijmegen breast cancer screening program became part of the national program. The Dutch government was responsible for the execution and quality control of the program and the training of the radiologists and radiographers. After the implementation period of the national program, the referral rate was found to be one percent ten per 1,000 women screened with a somewhat disappointing breast cancer detection rate. That result was the trigger to investigate the optimal referral rate in the early 2000s  ADDIN EN.CITE (17). Based on this so-called optimization study, the Dutch Expert Centre for Screening (LRCB) recommended an increase in the referral rate to twenty per 1,000 women screenedtwo percent. In 2007, the breast cancer screening program in Nijmegen switched to digital mammography instead of analogue mammography  ADDIN EN.CITE (18). This further increased the referral rate to around twenty-five per 1,000 women screened two and a half percent  ADDIN EN.CITE (19). 
Screening outcome data
During the forty years of breast cancer screening in Nijmegen, women in varying age ranges were invited, but women aged 50-69 were consistently invited over this period. For these women the following data  was collected: invitation for screening, participation in screening, referral for further diagnostic work-up and diagnosis of a screen-detected cancer or interval cancer (i.e. a cancer detected  between two consecutive screening rounds). These data were used for estimating test sensitivity of mammography and mean sojourn time. In order to investigate the effect of changes in mammographic technique and screening policy  on these two parameters, the data of the Nijmegen breast cancer screening program (1975-2012) was grouped in four periods; 1) pilot study in Nijmegen (1975-1988), 2) introduction of nationwide breast screening program (1989-2000), 3) publication of study on increasing the Dutch referral rate (2001-2006) and 4) introduction of digital mammography (2007-2012). For each of these periods we obtained estimates of test sensitivity, mean sojourn time and  the underlying breast cancer incidence. Because breast cancer screening in the Netherlands was implemented more than 25 years ago (1989), there was no suitable control group anymore or otherwise reliable estimate of the underlying breast cancer incidence available. Below we describe three methods for estimating test sensitivity of mammography and mean sojourn time based on modeling routine screening outcome data. 
Method 1: based on Maximum Likelihood Estimation 
Test sensitivity, mean sojourn time and underlying incidence were estimated based on empirical screening data. To determine the test sensitivity of mammography we calculated the ratio of the number of screen-detected cancers to the number of interval cancers diagnosed in the first year after screening plus all screen-detected cancers. The assumption was made that interval cancers detected in the first year after screening were missed cancers from the previous screen (20).
 Let λ1 be the underlying incidence of preclinical disease, λ2 be the rate of disease progression from preclinical to clinical phase and S the screening test sensitivity (of mammography). Let t be the interval between screens in years. Then at first screen, one would expect the proportion of persons found to have cancer to be 

At incident screens, the expected proportion is  ADDIN EN.CITE (21) 

The first term within the brackets is the probability of cancers newly arising in the preclinical phase since the last screen and not progressing to a clinical disease before the next screen. The second term is the probability of preclinical cancers missed at the previous screen which have not progressed to the clinical phase within the screening interval. There are two simplifying approximations here. The first is that the first term of the formula applies if the previous screen was also a subsequent (not a first) screen. Literature has shown that interval cancer rates after a subsequent screen are similar to interval cancer rates after a first screen (22). Applying this universally, regardless of the status of the previous screen, is therefore arguably a reasonable approximation. The second term is the absence of terms for cancers missed at screens before the last screen. Here, we are assuming that if a cancer is missed at a screen, it will either progress to a clinical disease in the subsequent interval, be detected at the subsequent screen or progress to a clinical disease in the interval following the subsequent screen. This is an approximation, however we assume that the probability of missed cancer at two successive screens is relatively small  This too is arguably a reasonable approximation as the probability of missed cancer at two successive screens is small  ADDIN EN.CITE (23).
The above formula with calculus then solves to 

The expected proportion of screen negative subjects having a clinical interval cancer before the next screen (making the same approximations as for subsequent screens) is

which solves to

Given these probabilities based on the three formulas for P, I and C, specific formulas for the log-likelihoods, separately for first and subsequent screens, were specified. After substituting the closed form estimates of S as above, Maximum Likelihood Estimation on the total log-likelihood was performed in order to get point estimates for λ1 and λ2. The point estimates of λ1 and λ2 were used to calculated the expected values of P, I and C. The 95% confidence intervals around these expected values were approximated and calculated by the following formula




Method 2: based on Non-Linear Regression 
If test sensitivity calculated under the assumption that interval cancers in the first year after screening are missed cancers is not adequately describing the real test sensitivity of mammography, a more complex estimation method is needed to estimate the three parameters at once. Then, a three-state Markov model can be applied to depict the progression process of breast cancer from the states of free from breast cancer (state 0), preclinical disease (state 1), and clinical disease (state 2). Breast cancers detected at screens were those in the preclinical detectable phase (PCDP) and interval breast cancers were in the clinical phase (CP)  ADDIN EN.CITE (24, 25). Let the underlying incidence of preclinical disease and the rate of disease progression from preclinical to clinical phase be denoted as above by λ1 and λ2, respectively. The intensity matrix of the three-state model is thus

	
and the corresponding transition probability matrix for interval between screens in years t 


With the following definitions
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The probabilities of observing preclinical cancers and subjects free from breast cancer in the prevalent screening round are thus
,
 (A)
where vm is age at prevalent screen. The probabilities of observing clinical disease, preclinical disease, and subjects free from breast cancer in the subsequent round are thus 


 (B)
where t is the interval between screens in years . For those with preclinical disease or free of breast cancer in the subsequent screen, t=2 due to the biennial screening interval in the Nijmegen breast cancer screening program. For clinical cancers, t is the corresponding time between two screens. Estimation of parameters was performed from the above series of equations by letting the observed numbers equal the expected plus an error term for each mode of detection using Non-Linear Regression  ADDIN EN.CITE (24, 25). For the estimation of test sensitivity, the probabilities in formula (A) and (B) were extended as follows
,
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where F0 represents the total of breast cancers detected in the previous screen round and n0 represents the number of attendees at previous screens  ADDIN EN.CITE (25). Considering the model taking into account the heterogeneity in transition rates, a regression model was adopted as follows

			              
where X is a vector of dummy variables corresponding to each period with the effect on underlying breast cancer incidence rate and rate of progression through regression coefficients β1 and β2, respectively and λ10 and λ20 represent the baseline transition rates. The heterogeneity in sensitivity (S) of each period was modeled using a logistic form

The parameters were estimated by Non-Linear Regression, with the expected numbers of cancers at first and subsequent screens, and numbers of interval cancers based on the above formulae as the regression predictor and the observed numbers as the dependent variable (24).
Method 3: based on Markov Chain Monte Carlo simulation (MCMC) 
We also applied Markov Chain Monte Carlo simulation (MCMC) to estimate the parameters from the model described above. The same formulae for probabilities and expectations were used, but the parameters were assigned vague prior distributions and estimated in a Bayesian framework using MCMC (26). A Gibbs sampler was used to derive samples of a stationary posterior distribution by which inferences on parameters were drawn. A thinning interval of 3 with a burn-in interval of 10,000 and a total of 15,000 iterations were used which yields a total of 5,000 updated posterior samples.


Results
The number of invited, screened and referred women over the four periods as well as the number of screen-detected and interval cancers are presented in Table 1. The attendance rate has steadily increased over the four periods. The referral rate was stable in period 1 and 2, but increased during the last two periods to 29 per 1,000 women screened. The first rise in the referral rate coincided with  the optimization study and the recommendation to increase referral  ADDIN EN.CITE (17). The second rise was seen after the introduction of digital mammography. With digital mammography, period 4, the screen-detected cancer rate increased from five tumors per 1,000 women screened to almost seven tumors per 1,000 women screened  ADDIN EN.CITE (19, 27). Moreover, the number of screen-detected ductal carcinomas in situ (DCIS) was also higher. However, the interval cancer rate remained stable over the four periods. 
In Table 2, the estimates for test sensitivity, the underlying breast cancer incidence and mean sojourn time over the four periods calculated by each of the three methods (MLE, NLR, MCMC) are given. The estimated underlying breast cancer incidence  has risen with approximately one case per 1,000 women per year in the final period compared to the first for all methods. The calculated test sensitivity of mammography using MLE was around 90%.  In contrast, the estimated test sensitivity using NLR and MCMC showed a higher sensitivity in period 4 (86% and 79%, respectively) compared to the previous periods. The estimates of mean sojourn time remained fairly stable over the first three periods, whereas the point estimates of all methods showed a small increase in period 4 compared to period 3 (MLE: 2.4 vs. 3.3, NLR: 3.6 vs. 4.4, MCMC: 4.3 vs. 4.6) . The mean sojourn time estimated based on MLE was 3 years, while the estimates of NLR and MCMC were closer to 4 years.



Table 1. Number of Invited, Screened, and Referred Women (aged 50-69) and Number of Screen-detected and Interval-detected Cancers for all Screens and First and Subsequent Screens Separately in the Nijmegen Breast Cancer Screening Program in the Period 1975-2012
	Period 1 1975-1988	Period 21989-2000	Period 32001-2006	Period 4 2007-2012
All screens				
Invited	99,702	85,320	46,816	51,767
Screened	65,404	59,208	35,958	40,107
Attendance rate (%)	66	69	77	78
Referred	545	493	504	1168
Referral rate (per 1,000 women screened)	8.3	8.3	14.0	29.1
Screen-detected cancer*	260 (40) 	263 (35)	175 (24)	263 (60)
Screen-detected rate (per 1,000 women screened)	4.0	4.4	4.9	6.6
Interval cancer	130	121	82	84
Interval cancer rate (per 1,000 women screened)	2.0	2.0	2.3	2.1
Interval cancer year 1	38	38	20	30
Interval cancer year 2	92	83	62	54
First screens				
Screened	12,317	3,007	4,163	4,907
Attendance rate (%)	96.4	90.7	96.9	88.6
Referred	182	50	100	306
Referral rate (per 1,000 women screened)	14.8	16.6	24.0	62.4
Screen-detected cancer	69	23	20	49
Screen-detected rate (per 1,000 women screened)	5.6	7.6	4.8	10.0
Interval cancer	18	7	11	13
Interval cancer year 1	3	3	3	5
Interval cancer year 2	15	4	8	8
Subsequent screens				
Screened	53,087	56,201	31,795	35,200
Attendance rate (%)	62.6	68.5	74.8	76.1
Referred	363	443	404	862
Referral rate (per 1,000 women screened)	6.8	7.9	12.7	24.5
Screen-detected cancer	191	240	155	214
Screen-detected rate (per 1,000 women screened)	3.6	4.3	4.9	6.1
Interval cancer	112	114	71	71
Interval cancer year 1	35	35	17	25
Interval cancer year 2	77	79	54	46
*in parentheses, the number of ductal carcinoma in situ (DCIS) out of the total number of cancers



Table 2. Estimation of Mammography Sensitivity (S), Mean Sojourn Time (MST), Underlying Breast Cancer Incidence (λ1), Using Three Estimation Methods Applied to Data From Women Aged 50-69 When Invited to Participate in the Nijmegen Breast Cancer Screening Program in 1975-2012
	Period 1 1975-1988	Period 21989-2000	Period 32001-2006	Period 4 2007-2012
	 S (%)	MST (years)	λ1 (per 1,000 women per year)	 S (%)	MST (years)	λ1 (per 1,000 women per year)	 S (%)	MST (years)	λ1 (per 1,000 women per year)	 S (%)	MST (years)	λ1 (per 1,000 women per year)
Method 1 MLE	87(83-91)	2.5 
(2.1-2.9)	2.8 (2.5-3.0)	87(84-91)	2.9 
(2.4-3.5)	3.2(2.9-3.4)	90(85-94)	2.4 
(2.0-3.0)	3.4(3.1-3.8)	90(86-93)	3.3
 (2.8-4.0)	4.0(3.6-4.4)
Method 2 NLR	81 (60-92)	3.1 (2.2-5.2)	2.0 (1.7-2.3)	80 (35-97)	3.0 (1.4-6.6)	2.9 (1.7-5.0)	72 (24-95)	3.6 (1.6-8.2)	2.4 (1.4-3.9)	86 (43-98)	4.4 (1.9-10.0)	3.0 (1.8-5.0)
Method 3 MCMC	75(65-84)	3.4 (2.7-4.3)	2.4 (2.1-2.6)	75 (67-81)	3.4 (2.9-4.2)	2.5 (2.3-3.6)	70 (58-82)	4.3 (3.1-5.7)	3.2 (2.8-3.6)	79 (70-87)	4.6 (3.7-5.9)	3.5 (3.2-3.9)
MLE= maximum likelihood estimation; NLR= Non-Linear Regression; MCMC= Markov chain Monte Carlo 
Within parentheses, 95% confidence interval




Discussion

Our analysis over forty years of breast cancer screening in Nijmegen showed a trend towards higher test sensitivity and longer mean sojourn time after the introduction of digital mammography. The three methods used for obtaining estimates of mammography test sensitivity and mean sojourn time gave comparable results. However, the more sophisticated methods, NLR and MCMC, which also estimated test sensitivity from empirical screening data, showed more realistic estimates. 

The three methods applied in this study have been used previously to estimate test sensitivity and mean sojourn time, but have never been used to investigate these parameters over time as well as been directly compared to one another before. Our estimates of mean sojourn time during the period of analogue mammography (period 1-3) are comparable to previous found results  ADDIN EN.CITE (24, 25). In contrast, the results of period 4 are difficult to compare to what is known, because to our knowledge there are no other estimates of mean sojourn time based on digital mammography. The slight increase in test sensitivity after the introduction of digital mammography has been found previously  ADDIN EN.CITE (19, 27, 28).

A major strength of our study is that we were able to investigate the consequences of changes in the screening program on important parameters for the screening interval over a forty year follow-up period in a well-documented screening program. Since the Nijmegen screening program has been running for decades now, there were no women who were not invited for screening or reliable estimate of the underlying breast cancer incidence available. Therefore the underlying breast cancer incidence also needed to be estimated. The estimated underlying breast cancer incidence showed an upwards trend over the four periods. An similar trend in the breast cancer incidence was seen in women aged 45-49 in the Netherlands (unscreened population) (29). This can be explained by  opportunistic screening and an increase in breast cancer risk factors. Furthermore, with the found stable interval cancer rates and the higher screen detection rates, this supports a real increase in the incidence and not an increase in overdiagnosis. We also found that the results of the three methods correlated well, which may suggest that the estimates are accurate, also in comparison with previously published results for screening with analogue mammography  ADDIN EN.CITE (24, 30). 

Another strength is that our approach can easily be applied to other (breast) cancer screening programs that want to investigate the impact of changes in their screening program on test sensitivity and sojourn time. The MLE method with a very simple closed form approximation for sensitivity, gave rather high estimates for sensitivity in the early periods, but is fairly easy to use. Moreover this method is more constrained than the other two methods and arguably gives confidence intervals that are too small, not reflecting the entire uncertainty in the data. It may be that the approximations used in this method were less accurate than those in the more sophisticated methods (NLR, MCMC). NLR assumes a Poisson distribution of observed total numbers with their expectations which leads to very wide confidence intervals. MCMC takes account of the conditionalities of these distributions on the distributions of related variables, and could therefore be argued to model more closely the interrelationships in the data and the model parameters. Thus, MCMC has arguably the most realistic confidence interval estimates. As there is no gold standard for estimating mean sojourn time, it is difficult to judge which of these three estimation methods has the most reliable outcome. Furthermore, iIn our selection of methods, we chose methods that can be applied to routinely collected screening data instead of more complex data such as tumor size for calculating tumor volume/doubling times. 

An important limitation  is the size of our dataset as we use data from a breast cancer screening program in a single city in the Netherlands. Because of the limited number of cancers detected and wide confidence intervals, our results need to be interpreted with caution. Nonetheless, all three methods, especially NLR and MCMC, gave the impression that mean sojourn time is longer after the introduction of digital mammography. The point estimate of mean sojourn time is almost 1.5 year longer as when the screening program started (NLR: 3.1 vs. 4.4 year, MCMC: 3.4 vs. 4.6 year). This may be seen as the first piece of evidence towards considering a longer screening interval. In order to be more certain about our findings, validation of the results in a larger data set would be the next step. Furthermore, since not all breast cancers have a mammographically detectable preclinical phase, we can estimate the mean sojourn time only as an average for the breast cancers that can be detected by mammography and those that cannot. Moreover, it is likely that the prognosis of the cancer in these two groups is different, which may also have affected the estimates of MST  ADDIN EN.CITE (31). The potential introduction of new or additional screening modalities, such as digital breast tomosynthesis, automated breast ultrasound and breast MRI, will most likely make it possible to estimate the MST for a larger proportion of all breast cancers. Future research should also include estimating test sensitivity and mean sojourn time for subgroups of women at varying levels of breast cancer risk. This could underpin the length of the screening interval for subgroups of  women in the move towards a risk-based breast cancer screening program rather than the one-size-fits-all approach based on age alone. 

In conclusion, this study shows that test sensitivity and mean sojourn time, while taking the underlying breast cancer incidence rate into account, can be investigated based on routinely available screening data, with more complex methods providing the most realistic outcomes.



The authors declare that there is no conflict of interest.
References
1.	Netherlands HCot. Population screening for breast cancer: expectation and developments. The Haque: Health Council of the Netherlands; 2014.2.	Verbeek AL, Hendriks JH, Holland R, Mravunac M, Sturmans F, Day NE. Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981. Lancet (London, England). 1984;1(8388):1222-4.3.	Collette HJ, Day NE, Rombach JJ, de Waard F. Evaluation of screening for breast cancer in a non-randomised study (the DOM project) by means of a case-control study. Lancet (London, England). 1984;1(8388):1224-6.4.	Prevost TC, Launoy G, Duffy SW, Chen HH. Estimating sensitivity and sojourn time in screening for colorectal cancer: a comparison of statistical approaches. American journal of epidemiology. 1998;148(6):609-19.5.	Jiang H, Walter SD, Brown PE, Chiarelli AM. Estimation of screening sensitivity and sojourn time from an organized screening program. Cancer epidemiology. 2016;44:178-85.6.	Lundgren B. Observations on growth rate of breast carcinomas and its possible implications for lead time. Cancer. 1977;40(4):1722-5.7.	Otten JD, van Schoor G, Peer PG, den Heeten GJ, Holland R, Broeders MJ, et al. Growth rate of invasive ductal carcinomas from a screened 50-74-year-old population. Journal of medical screening. 2017:969141316687791.8.	Zelen M, Feinleib M. On the theory of screening for chronic diseases. Biometrika. 1969;56(3):601-14.9.	Day NE, Walter SD. Simplified models of screening for chronic disease: estimation procedures from mass screening programmes. Biometrics. 1984;40(1):1-14.10.	Paci E, Duffy SW. Modelling the analysis of breast cancer screening programmes: sensitivity, lead time and predictive value in the Florence District Programme (1975-1986). International journal of epidemiology. 1991;20(4):852-8.11.	Chen JS, Prorok PC. Lead time estimation in a controlled screening program. American journal of epidemiology. 1983;118(5):740-51.12.	van Oortmarssen GJ, Habbema JD, Lubbe JT, van der Maas PJ. A model-based analysis of the HIP project for breast cancer screening. International journal of cancer. 1990;46(2):207-13.13.	Duffy SW, Chen HH, Tabar L, Day NE. Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase. Statistics in medicine. 1995;14(14):1531-43.14.	van Luijt PA, Fracheboud J, Heijnsdijk EA, den Heeten GJ, de Koning HJ. Nation-wide data on screening performance during the transition to digital mammography: observations in 6 million screens. European journal of cancer (Oxford, England : 1990). 2013;49(16):3517-25.15.	Otten JD, van Dijck JA, Peer PG, Straatman H, Verbeek AL, Mravunac M, et al. Long term breast cancer screening in Nijmegen, The Netherlands: the nine rounds from 1975-92. Journal of epidemiology and community health. 1996;50(3):353-8.16.	Gezondheidsraad. De vroeg opsporing van borstkanker. Den Haag: Gezondheidsraad; 1987.17.	Otten JD, Karssemeijer N, Hendriks JH, Groenewoud JH, Fracheboud J, Verbeek AL, et al. Effect of recall rate on earlier screen detection of breast cancers based on the Dutch performance indicators. Journal of the National Cancer Institute. 2005;97(10):748-54.18.	Timmers JM, den Heeten GJ, Adang EM, Otten JD, Verbeek AL, Broeders MJ. Dutch digital breast cancer screening: implications for breast cancer care. European journal of public health. 2012;22(6):925-9.19.	Bluekens AM, Holland R, Karssemeijer N, Broeders MJ, den Heeten GJ. Comparison of digital screening mammography and screen-film mammography in the early detection of clinically relevant cancers: a multicenter study. Radiology. 2012;265(3):707-14.20.	Michell M. Breast Cancer: Cambridge University Press; 2010.21.	Michalopoulos D, Duffy SW. Estimation of overdiagnosis using short-term trends and lead time estimates uncontaminated by overdiagnosed cases: Results from the Norwegian Breast Screening Programme. Journal of medical screening. 2016;23(4):192-202.22.	Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Grontoft O. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiologic clinics of North America. 1992;30(1):187-210.23.	Duffy SW, Agbaje O, Tabar L, Vitak B, Bjurstam N, Bjorneld L, et al. Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast cancer research : BCR. 2005;7(6):258-65.24.	Chen HH, Duffy SW, Tabar L. A Markov chain method to estimate the tumour progression rate from preclinical to clinical phase, sensitivity, and positive predictive value for mammography in breast cancer screening. The Statistician. 1996(45):307-17.25.	Chen TH, Kuo HS, Yen MF, Lai MS, Tabar L, Duffy SW. Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics. 2000;56(1):167-72.26.	Chien CR, Lai MS, Chen TH. Estimation of mean sojourn time for lung cancer by chest X-ray screening with a Bayesian approach. Lung cancer (Amsterdam, Netherlands). 2008;62(2):215-20.27.	Bluekens AM, Karssemeijer N, Beijerinck D, Deurenberg JJ, van Engen RE, Broeders MJ, et al. Consequences of digital mammography in population-based breast cancer screening: initial changes and long-term impact on referral rates. European radiology. 2010;20(9):2067-73.28.	Karssemeijer N, Bluekens AM, Beijerinck D, Deurenberg JJ, Beekman M, Visser R, et al. Breast cancer screening results 5 years after introduction of digital mammography in a population-based screening program. Radiology. 2009;253(2):353-8.29.	Nederlands Ik. Cijfers over kanker 2018 [Available from: https://www.cijfersoverkanker.nl/selecties/incidentie_borst/img5ac4d3b768154?xaxis=period.30.	Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001;19(15):3490-9.31.	Tabar L, Dean PB, Yen AM, Tarjan M, Chiu SY, Chen SL, et al. A Proposal to Unify the Classification of Breast and Prostate Cancers Based on the Anatomic Site of Cancer Origin and on Long-term Patient Outcome. Breast cancer : basic and clinical research. 2014;8:15-38.
2.	Verbeek AL, Hendriks JH, Holland R, Mravunac M, Sturmans F, Day NE. Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981. Lancet (London, England). 1984;1(8388):1222-4.
3.	Collette HJ, Day NE, Rombach JJ, de Waard F. Evaluation of screening for breast cancer in a non-randomised study (the DOM project) by means of a case-control study. Lancet (London, England). 1984;1(8388):1224-6.
4.	Prevost TC, Launoy G, Duffy SW, Chen HH. Estimating sensitivity and sojourn time in screening for colorectal cancer: a comparison of statistical approaches. American journal of epidemiology. 1998;148(6):609-19.
5.	Jiang H, Walter SD, Brown PE, Chiarelli AM. Estimation of screening sensitivity and sojourn time from an organized screening program. Cancer epidemiology. 2016;44:178-85.
6.	Lundgren B. Observations on growth rate of breast carcinomas and its possible implications for lead time. Cancer. 1977;40(4):1722-5.
7.	Otten JD, van Schoor G, Peer PG, den Heeten GJ, Holland R, Broeders MJ, et al. Growth rate of invasive ductal carcinomas from a screened 50-74-year-old population. Journal of medical screening. 2017:969141316687791.
8.	Zelen M, Feinleib M. On the theory of screening for chronic diseases. Biometrika. 1969;56(3):601-14.
9.	Day NE, Walter SD. Simplified models of screening for chronic disease: estimation procedures from mass screening programmes. Biometrics. 1984;40(1):1-14.
10.	Paci E, Duffy SW. Modelling the analysis of breast cancer screening programmes: sensitivity, lead time and predictive value in the Florence District Programme (1975-1986). International journal of epidemiology. 1991;20(4):852-8.
11.	Chen JS, Prorok PC. Lead time estimation in a controlled screening program. American journal of epidemiology. 1983;118(5):740-51.
12.	van Oortmarssen GJ, Habbema JD, Lubbe JT, van der Maas PJ. A model-based analysis of the HIP project for breast cancer screening. International journal of cancer. 1990;46(2):207-13.
13.	Duffy SW, Chen HH, Tabar L, Day NE. Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase. Statistics in medicine. 1995;14(14):1531-43.
14.	van Luijt PA, Fracheboud J, Heijnsdijk EA, den Heeten GJ, de Koning HJ. Nation-wide data on screening performance during the transition to digital mammography: observations in 6 million screens. European journal of cancer (Oxford, England : 1990). 2013;49(16):3517-25.
15.	Otten JD, van Dijck JA, Peer PG, Straatman H, Verbeek AL, Mravunac M, et al. Long term breast cancer screening in Nijmegen, The Netherlands: the nine rounds from 1975-92. Journal of epidemiology and community health. 1996;50(3):353-8.
16.	Gezondheidsraad. De vroeg opsporing van borstkanker. Den Haag: Gezondheidsraad; 1987.
17.	Otten JD, Karssemeijer N, Hendriks JH, Groenewoud JH, Fracheboud J, Verbeek AL, et al. Effect of recall rate on earlier screen detection of breast cancers based on the Dutch performance indicators. Journal of the National Cancer Institute. 2005;97(10):748-54.
18.	Timmers JM, den Heeten GJ, Adang EM, Otten JD, Verbeek AL, Broeders MJ. Dutch digital breast cancer screening: implications for breast cancer care. European journal of public health. 2012;22(6):925-9.
19.	Bluekens AM, Holland R, Karssemeijer N, Broeders MJ, den Heeten GJ. Comparison of digital screening mammography and screen-film mammography in the early detection of clinically relevant cancers: a multicenter study. Radiology. 2012;265(3):707-14.
20.	Michell M. Breast Cancer: Cambridge University Press; 2010.
21.	Michalopoulos D, Duffy SW. Estimation of overdiagnosis using short-term trends and lead time estimates uncontaminated by overdiagnosed cases: Results from the Norwegian Breast Screening Programme. Journal of medical screening. 2016;23(4):192-202.
22.	Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Grontoft O. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiologic clinics of North America. 1992;30(1):187-210.
23.	Duffy SW, Agbaje O, Tabar L, Vitak B, Bjurstam N, Bjorneld L, et al. Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast cancer research : BCR. 2005;7(6):258-65.
24.	Chen HH, Duffy SW, Tabar L. A Markov chain method to estimate the tumour progression rate from preclinical to clinical phase, sensitivity, and positive predictive value for mammography in breast cancer screening. The Statistician. 1996(45):307-17.
25.	Chen TH, Kuo HS, Yen MF, Lai MS, Tabar L, Duffy SW. Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics. 2000;56(1):167-72.
26.	Chien CR, Lai MS, Chen TH. Estimation of mean sojourn time for lung cancer by chest X-ray screening with a Bayesian approach. Lung cancer (Amsterdam, Netherlands). 2008;62(2):215-20.
27.	Bluekens AM, Karssemeijer N, Beijerinck D, Deurenberg JJ, van Engen RE, Broeders MJ, et al. Consequences of digital mammography in population-based breast cancer screening: initial changes and long-term impact on referral rates. European radiology. 2010;20(9):2067-73.
28.	Karssemeijer N, Bluekens AM, Beijerinck D, Deurenberg JJ, Beekman M, Visser R, et al. Breast cancer screening results 5 years after introduction of digital mammography in a population-based screening program. Radiology. 2009;253(2):353-8.
29.	Nederlands Ik. Cijfers over kanker 2018 [Available from: https://www.cijfersoverkanker.nl/selecties/incidentie_borst/img5ac4d3b768154?xaxis=period.
30.	Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001;19(15):3490-9.
31.	Tabar L, Dean PB, Yen AM, Tarjan M, Chiu SY, Chen SL, et al. A Proposal to Unify the Classification of Breast and Prostate Cancers Based on the Anatomic Site of Cancer Origin and on Long-term Patient Outcome. Breast cancer : basic and clinical research. 2014;8:15-38.




23



